Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer.
Schmitz-Winnenthal FH, Hohmann N, Schmidt T, Podola L, Friedrich T, Lubenau H, Springer M, Wieckowski S, Breiner KM, Mikus G, Büchler MW, Keller AV, Koc R, Springfeld C, Knebel P, Bucur M, Grenacher L, Haefeli WE, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: podola l. Oncoimmunology. 2018 Jan 16;7(4):e1303584. doi: 10.1080/2162402X.2017.1303584. eCollection 2018. Oncoimmunology. 2018. PMID: 29632710 Free PMC article.
Phase II trial of ipilimumab in melanoma patients with preexisting humoural immune response to NY-ESO-1.
Haag GM, Zoernig I, Hassel JC, Halama N, Dick J, Lang N, Podola L, Funk J, Ziegelmeier C, Juenger S, Bucur M, Umansky L, Falk CS, Freitag A, Karapanagiotou-Schenkel I, Beckhove P, Enk A, Jaeger D. Haag GM, et al. Among authors: podola l. Eur J Cancer. 2018 Feb;90:122-129. doi: 10.1016/j.ejca.2017.12.001. Epub 2018 Jan 5. Eur J Cancer. 2018. PMID: 29306769 Clinical Trial.
Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A, Podola L, Mann P, Missanga M, Haule A, Sudi L, Nilsson C, Kaluwa B, Lueer C, Mwakatima M, Munseri PJ, Maboko L, Robb ML, Tovanabutra S, Kijak G, Marovich M, McCormack S, Joseph S, Lyamuya E, Wahren B, Sandström E, Biberfeld G, Hoelscher M, Bakari M, Kroidl A, Geldmacher C. Bauer A, et al. Among authors: podola l. J Virol. 2017 Aug 24;91(18):e00730-17. doi: 10.1128/JVI.00730-17. Print 2017 Sep 15. J Virol. 2017. PMID: 28701395 Free PMC article.
CD25+ FoxP3+ Memory CD4 T Cells Are Frequent Targets of HIV Infection In Vivo.
Chachage M, Pollakis G, Kuffour EO, Haase K, Bauer A, Nadai Y, Podola L, Clowes P, Schiemann M, Henkel L, Hoffmann D, Joseph S, Bhuju S, Maboko L, Sarfo FS, Eberhardt K, Hoelscher M, Feldt T, Saathoff E, Geldmacher C. Chachage M, et al. Among authors: podola l. J Virol. 2016 Sep 29;90(20):8954-67. doi: 10.1128/JVI.00612-16. Print 2016 Oct 15. J Virol. 2016. PMID: 27384654 Free PMC article.
Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial.
Schmitz-Winnenthal FH, Hohmann N, Niethammer AG, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Schmitz-Winnenthal FH, et al. Among authors: podola l. Oncoimmunology. 2015 Mar 16;4(4):e1001217. doi: 10.1080/2162402X.2014.1001217. eCollection 2015 Apr. Oncoimmunology. 2015. PMID: 26137397 Free PMC article.
Priming with a simplified intradermal HIV-1 DNA vaccine regimen followed by boosting with recombinant HIV-1 MVA vaccine is safe and immunogenic: a phase IIa randomized clinical trial.
Munseri PJ, Kroidl A, Nilsson C, Joachim A, Geldmacher C, Mann P, Moshiro C, Aboud S, Lyamuya E, Maboko L, Missanga M, Kaluwa B, Mfinanga S, Podola L, Bauer A, Godoy-Ramirez K, Marovich M, Moss B, Hoelscher M, Gotch F, Stöhr W, Stout R, McCormack S, Wahren B, Mhalu F, Robb ML, Biberfeld G, Sandström E, Bakari M. Munseri PJ, et al. Among authors: podola l. PLoS One. 2015 Apr 15;10(4):e0119629. doi: 10.1371/journal.pone.0119629. eCollection 2015. PLoS One. 2015. PMID: 25875843 Free PMC article. Clinical Trial.
Identification of NY-BR-1-specific CD4(+) T cell epitopes using HLA-transgenic mice.
Gardyan A, Osen W, Zörnig I, Podola L, Agarwal M, Aulmann S, Ruggiero E, Schmidt M, Halama N, Leuchs B, von Kalle C, Beckhove P, Schneeweiss A, Jäger D, Eichmüller SB. Gardyan A, et al. Among authors: podola l. Int J Cancer. 2015 Jun 1;136(11):2588-97. doi: 10.1002/ijc.29322. Epub 2014 Nov 26. Int J Cancer. 2015. PMID: 25387692
Helminth-associated systemic immune activation and HIV co-receptor expression: response to albendazole/praziquantel treatment.
Chachage M, Podola L, Clowes P, Nsojo A, Bauer A, Mgaya O, Kowour D, Froeschl G, Maboko L, Hoelscher M, Saathoff E, Geldmacher C. Chachage M, et al. Among authors: podola l. PLoS Negl Trop Dis. 2014 Mar 27;8(3):e2755. doi: 10.1371/journal.pntd.0002755. eCollection 2014 Mar. PLoS Negl Trop Dis. 2014. PMID: 24675895 Free PMC article.